James Perry

18.0k total citations · 3 hit papers
203 papers, 7.7k citations indexed

About

James Perry is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, James Perry has authored 203 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Genetics, 64 papers in Pulmonary and Respiratory Medicine and 46 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in James Perry's work include Glioma Diagnosis and Treatment (104 papers), Brain Metastases and Treatment (47 papers) and Radiomics and Machine Learning in Medical Imaging (23 papers). James Perry is often cited by papers focused on Glioma Diagnosis and Treatment (104 papers), Brain Metastases and Treatment (47 papers) and Radiomics and Machine Learning in Medical Imaging (23 papers). James Perry collaborates with scholars based in Canada, United States and Germany. James Perry's co-authors include Wolfgang Wick, Michael Weller, Normand Laperrière, Timothy F. Cloughesy, Arjun Sahgal, William Geerts, Warren Mason, Juan M. Bilbao, Nir Lipsman and Alexandra Chambers and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Investigation.

In The Last Decade

James Perry

190 papers receiving 7.5k citations

Hit Papers

Standards of care for treatment of recurrent glioblastoma... 2012 2026 2016 2021 2012 2019 2024 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Standards of care for treatment of recurrent glioblastoma—are we there yet?
    2012 587 citations Michael Weller, Timothy F. Cloughesy et al. Neuro-Oncology profile →
  2. Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study
    2019 464 citations Nir Lipsman, Chris Heyn et al. profile →
  3. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
    2024 124 citations Shubham Pant, Zev A. Wainberg et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Perry Canada 43 3.3k 1.8k 1.6k 1.3k 1.2k 203 7.7k
Ian F. Parney United States 49 4.3k 1.3× 2.2k 1.2× 2.1k 1.3× 1.5k 1.2× 1.5k 1.3× 198 9.3k
Uwe Pichlmeier Germany 45 3.1k 0.9× 2.7k 1.5× 1.2k 0.8× 1.2k 1.0× 1.4k 1.2× 118 8.6k
Xiaobu Ye United States 39 2.3k 0.7× 1.4k 0.8× 1.3k 0.8× 771 0.6× 946 0.8× 151 6.8k
Michael Bamberg Germany 45 2.6k 0.8× 2.3k 1.3× 1.3k 0.8× 1.0k 0.8× 895 0.8× 179 6.9k
Lukas J.A. Stalpers Netherlands 47 1.9k 0.6× 2.2k 1.2× 1.1k 0.7× 1.8k 1.4× 1.1k 1.0× 212 8.3k
Chetan Bettegowda United States 43 1.9k 0.6× 1.9k 1.0× 2.3k 1.4× 548 0.4× 803 0.7× 306 8.7k
G. Noël France 46 1.6k 0.5× 3.3k 1.8× 1.7k 1.1× 1.3k 1.0× 1.2k 1.0× 449 9.0k
Maximilian Niyazi Germany 40 2.1k 0.6× 2.3k 1.2× 1.1k 0.7× 2.2k 1.7× 1.1k 0.9× 270 6.2k
Shiao Y. Woo United States 52 2.4k 0.7× 3.3k 1.8× 922 0.6× 1.1k 0.9× 1.4k 1.2× 175 7.3k
Reid C. Thompson United States 44 1.4k 0.4× 646 0.4× 1.7k 1.1× 666 0.5× 776 0.7× 212 6.4k

Countries citing papers authored by James Perry

Since Specialization
Citations

This map shows the geographic impact of James Perry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Perry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Perry more than expected).

Fields of papers citing papers by James Perry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Perry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Perry. The network helps show where James Perry may publish in the future.

Co-authorship network of co-authors of James Perry

This figure shows the co-authorship network connecting the top 25 collaborators of James Perry. A scholar is included among the top collaborators of James Perry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Perry. James Perry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wainberg, Zev A., Colin D. Weekes, Muhammad Furqan, et al.. (2025). Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nature Medicine. 31(11). 3648–3653. 7 indexed citations
2.
Myrehaug, Sten, James T. Stewart, Jay Detsky, et al.. (2025). Temporal Apparent Diffusion Coefficient Changes During Chemoradiation: An Imaging Biomarker for Tumor Response Monitoring and Spatial Recurrence Prediction in Glioblastoma. International Journal of Radiation Oncology*Biology*Physics. 122(3). 592–604.
3.
Mason, Warren, Rebecca A. Harrison, Sarah Lapointe, et al.. (2025). Canadian Expert Consensus Recommendations for the Diagnosis and Management of Glioblastoma: Results of a Delphi Study. Current Oncology. 32(4). 207–207. 3 indexed citations
4.
Ong, Wee Loon, James Stewart, Arjun Sahgal, et al.. (2024). Predictors of Tumor Dynamics Over a 6-Week Course of Concurrent Chemoradiotherapy for Glioblastoma and the Effect on Survival. International Journal of Radiation Oncology*Biology*Physics. 120(3). 750–759. 3 indexed citations
5.
Groot, John Frederick De, Timothy F. Cloughesy, Donald A. Berry, et al.. (2024). Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology. 42(16_suppl). 2005–2005.
6.
7.
8.
Pant, Shubham, Zev A. Wainberg, Colin D. Weekes, et al.. (2024). Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nature Medicine. 30(2). 531–542. 124 indexed citations breakdown →
9.
Heyn, Chris, Alan R. Moody, Erin Wong, et al.. (2024). Gadolinium-Enhanced T2 FLAIR Is an Imaging Biomarker of Radiation Necrosis and Tumor Progression in Patients with Brain Metastases. American Journal of Neuroradiology. 46(1). 129–135. 3 indexed citations
10.
Hegi, Monika E., Felix Boakye Oppong, James Perry, et al.. (2024). No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients. Neuro-Oncology. 26(10). 1867–1875. 16 indexed citations
11.
Mohile, Nimish, Hans Messersmith, Na Tosha Gatson, et al.. (2021). Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Neuro-Oncology. 24(3). 358–383. 12 indexed citations
12.
Song, Andrew, Keyue Ding, Iyad Alnahhas, et al.. (2021). Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG08.02) randomized clinical trial. Neuro-Oncology Advances. 3(1). vdab153–vdab153. 12 indexed citations
13.
Chan, Rachel W., Hanbo Chen, Sten Myrehaug, et al.. (2020). Quantitative CEST and MT at 1.5T for monitoring treatment response in glioblastoma: early and late tumor progression during chemoradiation. Journal of Neuro-Oncology. 151(2). 267–278. 30 indexed citations
14.
Brandes, Alba A., J. Gregory Cairncross, Keyue Ding, et al.. (2020). Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. Journal of Neuro-Oncology. 149(1). 65–71. 17 indexed citations
15.
Meng, Wei, Zhenqing Ye, Ri Cui, et al.. (2013). MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients with Lung Adenocarcinoma. Clinical Cancer Research. 19(19). 5423–5433. 93 indexed citations
16.
Perry, James, Karl Bélanger, Warren Mason, et al.. (2010). Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study. Journal of Clinical Oncology. 28(12). 2051–2057. 264 indexed citations
17.
Perry, James, Chris J. O’Callaghan, Keyue Ding, et al.. (2010). A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme. Neuro-Oncology. 12. 38–38. 16 indexed citations
18.
Tsao, Ming‐Sound, Paul Sanghera, Arjun Sahgal, et al.. (2008). Pseudo-progression Following Concurrent Radiotherapy and Temozolomide for Glioblastoma. International Journal of Radiation Oncology*Biology*Physics. 72(1). S198–S199. 1 indexed citations
19.
Meyers, Christina A. & James Perry. (2008). Cognition and Cancer: Cognition and the brain: measurement, tools, and interpretation. Cambridge University Press eBooks. 10 indexed citations
20.
Perry, James, J. P. Szalai, & John W. Norris. (1997). Consensus Against Both Endarterectomy and Routine Screening for Asymptomatic Carotid Artery Stenosis. Archives of Neurology. 54(1). 25–28. 98 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ian F. Parney Breakdown of academic impact, for papers by Uwe Pichlmeier Breakdown of academic impact, for papers by Xiaobu Ye Breakdown of academic impact, for papers by Michael Bamberg Breakdown of academic impact, for papers by Lukas J.A. Stalpers Breakdown of academic impact, for papers by Chetan Bettegowda Breakdown of academic impact, for papers by G. Noël Breakdown of academic impact, for papers by Maximilian Niyazi Breakdown of academic impact, for papers by Shiao Y. Woo Breakdown of academic impact, for papers by Reid C. Thompson
Rankless by CCL
2026